Nausap 150 Iv 150 mg Lyophilised powder for solution for infusion
PDF Leaflet Revision Date: 15 November 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.
Dosage (summary)
150 mg IV on Day 1, administered over 20-30 mins prior to chemotherapy.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated in pregnancy and lactation; hormonal contraceptive efficacy may be reduced.
Key Drug Interactions
- Warfarin
- CYP3A4 inhibitors
- CYP3A4 inducers
Contraindications
- Hypersensitivity to aprepitant
- Concurrent use with pimozide, terfenadine, astemizole, cisapride
Common side effects
- Dizziness
- Fatigue
- Headache
- Constipation
- Hiccups
Counselling Points
- Monitor INR in patients on warfarin
- Use non-hormonal contraception during and 28 days after treatment
- Caution when driving or operating machinery due to potential dizziness.
Serious warnings
- Hypersensitivity reactions
- Severe hepatic insufficiency caution
Important Disclaimer
The Nausap 150 Iv 150 mg Lyophilised powder for solution for infusion professional information leaflet below is the property of Dr Reddy’S Laboratories and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
